3bO is India’s first face mask that uses CeNSTech™ – a patented technology of CeNS, a Govt of India, Dept of Science & Technology Lab,
Category: Experimental
Fidelis Pharmaceuticals Launches New Ethiqa XR™ Long-Lasting Control of Post-Procedural Pain Relief for Laboratory Rats and Mice
Fidelis Pharmaceuticals today announced the availability of new Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL. Ethiqa XR is the only pharmaceutical grade extended-release buprenorphine specifically
Arbro Pharmaceuticals launches Arbro’s Ayush Kwath Powder Immunity Booster
Arbro Pharmaceutical, a 35-year-old Delhi based pharmaceutical company, launches its Ayush Kwath Powder at Rs. 215 (100gm). This Ayush kwath powder is approved by the
Launch of One-of-its-kind Covid-19 Home Care Services by Gleneagles Global Hospitals for Covid-19 Patients
As the pandemic grows and number of cases swells in major metros, the healthcare system is stretched to its limits. With more and more people
31-Year-Old Man with Heart Pumping of Merely 20%, Successfully Underwent Complex Emergency Surgery at Wockhardt Hospital During Lockdown
A team headed by Dr Upendra Bhalerao, Cardiovascular and Thoracic Surgeon at Wockhardt Hospital, Mira Road, gave a new lease of life to a patient who was
Coronavirus Impact on PPE and Ventilators, Beroe Analysis
The impact of COVID-19 on the medical devices industry is high, and is expected to have a medium-long term effect as the industry is witnessing
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020 Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage
Development of Drug Resistance in Colon Cancer Patients Contributed to Failure of Oxaliplatin-based HIPEC PRODIGE 7 Trial
Development of Drug Resistance in Colon Cancer Patients Contributed to Failure of Oxaliplatin-based HIPEC PRODIGE 7 Trial Investigators at MedStar Washington Hospital Center and Nagourney
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab)
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer